SCHEMBL30099082

SCHEMBL30099082

c1ccc(-n2ccc3cncnc32)cc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MKNK2 Q9HBH9 10/20 0.59
MKNK1 Q9BUB5 2/20 0.49
CYP1A2 P05177 5/20 0.43
CYP3A4 P08684 4/20 0.43
ALDH1A1 P00352 3/20 0.43
CYP2C9 P11712 3/20 0.43
HSD17B10 Q99714 3/20 0.43
MAPK1 P28482 3/20 0.42
USP2 O75604 3/20 0.42
CYP2C19 P33261 2/20 0.42
EGFR P00533 3/20 0.41
CLK4 Q9HAZ1 2/20 0.40
TSHR P16473 2/20 0.40
CDC7 O00311 1/20 0.40
CHEK1 O14757 1/20 0.40
AURKA O14965 1/20 0.40
DCLK1 O15075 1/20 0.40
MAPK13 O15264 1/20 0.40
PDPK1 O15530 1/20 0.40
DAPK3 O43293 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8801410 1.00 MKNK2 (0.59) MKNK2MKNK1CYP1A2CYP3A4ALDH1A1
SCHEMBL28303127 0.83 MKNK2 (0.60) MKNK2MKNK1CYP1A2CYP3A4ALDH1A1
SCHEMBL28303123 0.81 MKNK2 (0.58) MKNK2MKNK1GSK3BIRAK4
SCHEMBL23413110 0.81 MKNK2 (0.58) MKNK2MKNK1EGFRPI4KAPI4K2B
SCHEMBL29484990 0.79 MKNK2 (0.56) MKNK2MKNK1CYP1A2CYP3A4ALDH1A1
SCHEMBL28317574 0.78 MKNK2 (0.55) MKNK2MKNK1JAK2JAK3IRAK4
SCHEMBL28316686 0.77 MKNK2 (0.53) MKNK2MKNK1JAK2JAK3
SCHEMBL18789209 0.74 MKNK2 (1.00) MKNK2MKNK1MAPK9
SCHEMBL30093014 0.74 MKNK2 (0.62) MKNK2MKNK1CDC7CDK2
SCHEMBL23412407 0.74 MKNK2 (0.62) MKNK2MKNK1CDC7CDK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12612424-B2 HPK1 inhibitors and uses thereof REGOR PHARMACEUTICALS, INC. (US) 2026-04-28 US disclosed
US-20220389037-A1 HPK1 INHIBITORS AND USES THEREOF REGOR PHARMACEUTICALS, INC. 2022-12-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12612424-B2 HPK1 inhibitors and uses thereof NEK11, NEK1, CSNK1A1 MKNK2 190/4885MKNK1 121/4885CYP1A2 3048/4885
US-20220389037-A1 HPK1 INHIBITORS AND USES THEREOF HIPK1, SIK1, PGK1 MKNK2 87/4885MKNK1 32/4885CYP1A2 3915/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.